Brainstorm Cell Therapeutics I Financials
This page shows Brainstorm Cell Therapeutics I (BCLI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Funding dependence still defines BrainStorm, as expense cuts reduced burn faster than they rebuilt liquidity.
Operating cash burn was cut by roughly two-thirds between FY2021 and FY2024, yet cash on hand nearly vanished over the same stretch. That combination, alongside a current ratio falling from 3.7x to 0.04x, shows expense reduction bought time but did not create operations that refill the balance sheet.
By FY2025, total liabilities were about eleven times total assets, leaving very little balance-sheet cushion if obligations come due before new funding arrives. With only
Financing inflows in FY2023 and FY2024 were large enough to offset much of the annual cash burn, so survival depended on fresh capital rather than internally generated funds. Because no long-term debt is reported, that bridge appears to have come mainly from outside investors while working-capital pressure kept tightening.
Financial Health Signals
Brainstorm Cell Therapeutics I does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
Brainstorm Cell Therapeutics I earned -$1.11 per diluted share (EPS) in fiscal year 2025. This represents an increase of 51.9% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Brainstorm Cell Therapeutics I held $29K in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
None of these metrics is reported for fiscal year 2025.
Capital Allocation
Brainstorm Cell Therapeutics I invested $4.2M in research and development in fiscal year 2025. This represents a decrease of 10.2% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
BCLI Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | N/A | $4.2M-10.2% | $4.7M-56.7% | $10.7M-23.0% | $14.0M-8.4% | $15.2M-31.8% | $22.3M+29.8% | $17.2M+107.5% | $8.3M+748.8% | $977K-56.6% | $2.3M-54.5% | $4.9M+3.7% | $4.8M+63.6% | $2.9M+64.8% | $1.8M+4.8% | $1.7M |
| SG&A Expenses | N/A | N/A | $7.0M-34.1% | $10.7M-1.6% | $10.9M+16.8% | $9.3M-0.5% | $9.4M+61.4% | $5.8M+0.5% | $5.8M+43.5% | $4.0M+42.0% | $2.8M-21.0% | $3.6M+35.4% | $2.6M+24.6% | $2.1M+21.6% | $1.7M-20.7% | $2.2M |
| Operating Income | N/A | N/A | N/A | N/A | -$24.8M-1.2% | -$24.5M+22.6% | -$31.7M-37.8% | -$23.0M-63.6% | -$14.1M-181.3% | -$5.0M+1.7% | -$5.1M+40.5% | -$8.5M-15.0% | -$7.4M-51.5% | -$4.9M-43.0% | -$3.4M+12.5% | -$3.9M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -$93K-161.6% | $151K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 | $0 | $0 | $0 | $0-100.0% | $5K0.0% | $5K |
| Net Income | N/A | N/A | N/A | -$17.2M+29.2% | -$24.3M+0.7% | -$24.5M+23.1% | -$31.8M-36.8% | -$23.3M-66.7% | -$13.9M-181.7% | -$5.0M+0.6% | -$5.0M+41.3% | -$8.5M+8.2% | -$9.2M-88.7% | -$4.9M-42.8% | -$3.4M+12.5% | -$3.9M |
| EPS (Diluted) | — | -$1.11+51.9% | -$2.31+61.5% | -$6.00 | -$0.66+2.9% | -$0.68+36.4% | -$1.07 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
BCLI Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.0M-44.2% | $1.8M-56.5% | $4.2M-50.2% | $8.5M-71.1% | $29.3M-42.9% | $51.3M+684.5% | $6.5M-41.8% | $11.2M-1.7% | $11.4M+6.1% | $10.8M-37.0% | $17.1M+72.3% | $9.9M+109.7% | $4.7M-8.0% | $5.1M+87.2% | $2.7M |
| Current Assets | $307K-20.3% | $385K-79.7% | $1.9M-38.9% | $3.1M-86.7% | $23.3M-46.2% | $43.2M+1187.0% | $3.4M-67.3% | $10.3M+6.7% | $9.6M-7.9% | $10.4M-37.8% | $16.8M+75.3% | $9.6M+115.4% | $4.4M-8.8% | $4.9M+111.5% | $2.3M |
| Cash & Equivalents | $29K-84.5% | $187K-85.6% | $1.3M+68.4% | $772K-95.9% | $18.9M-50.2% | $37.8M+6957.6% | $536K-43.1% | $942K-62.1% | $2.5M+353.9% | $547K+27.8% | $428K-89.9% | $4.3M+21.4% | $3.5M+166.0% | $1.3M-31.5% | $1.9M |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $312K |
| Total Liabilities | $11.0M+14.7% | $9.6M+5.8% | $9.1M-20.9% | $11.5M+15.4% | $9.9M-37.1% | $15.8M-15.8% | $18.8M+201.9% | $6.2M+12.1% | $5.5M+541.6% | $864K-70.7% | $3.0M-8.8% | $3.2M+62.9% | $2.0M+71.9% | $1.2M-8.0% | $1.3M |
| Current Liabilities | $11.0M+22.6% | $9.0M+15.1% | $7.8M-11.4% | $8.8M+39.3% | $6.3M-43.8% | $11.2M-36.4% | $17.7M+184.2% | $6.2M+12.1% | $5.5M+541.6% | $864K-70.7% | $3.0M-5.2% | $3.1M+133.7% | $1.3M+15.2% | $1.2M+1.9% | $1.1M |
| Total Equity | -$10.0M-28.6% | -$7.8M-59.8% | -$4.9M-61.1% | -$3.0M-115.6% | $19.3M-45.5% | $35.5M+390.1% | -$12.2M-343.7% | $5.0M-14.7% | $5.9M-40.6% | $9.9M-29.9% | $14.1M+111.7% | $6.7M+143.7% | $2.7M-31.2% | $4.0M+167.6% | $1.5M |
| Retained Earnings | -$236.9M-4.5% | -$226.6M-5.4% | -$215.0M-8.7% | -$197.8M-14.0% | -$173.5M-16.4% | -$149.1M-27.1% | -$117.3M-24.7% | -$94.0M-17.4% | -$80.1M-6.6% | -$75.1M-7.1% | -$70.1M-13.8% | -$61.7M-17.6% | -$52.4M | N/A | N/A |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
BCLI Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$4.1M | N/A | -$9.1M+55.6% | -$20.5M-5.9% | -$19.3M+26.4% | -$26.3M+25.4% | -$35.2M-212.9% | -$11.2M+9.2% | -$12.4M-424.0% | -$2.4M+59.6% | -$5.9M+20.9% | -$7.4M-65.1% | -$4.5M-10.7% | -$4.1M-38.1% | -$2.9M-32.0% | -$2.2M |
| Capital Expenditures | N/A | N/A | N/A | $18K-37.9% | $29K-91.2% | $330K-12.7% | $378K-20.1% | $473K+28.2% | $369K+105.0% | $180K+74.8% | $103K+128.9% | $45K-72.0% | $161K+49.1% | $108K+20.0% | $90K+87.5% | $48K |
| Free Cash Flow | N/A | N/A | N/A | -$20.5M-5.8% | -$19.3M+27.2% | -$26.6M+25.2% | -$35.6M-203.5% | -$11.7M+8.1% | -$12.8M-401.5% | -$2.5M+57.3% | -$6.0M+20.0% | -$7.5M-60.3% | -$4.6M-11.7% | -$4.2M-37.6% | -$3.0M-33.2% | -$2.3M |
| Investing Cash Flow | N/A | N/A | $12K-99.5% | $2.2M+119.7% | $998K+209.0% | $323K+107.3% | -$4.5M-179.3% | $5.6M+561.1% | -$1.2M-130.6% | $4.0M-33.3% | $6.0M | N/A | -$4.5M-267.5% | $2.7M+193.5% | -$2.8M-4337.5% | -$64K |
| Financing Cash Flow | $3.2M | N/A | $8.0M-58.0% | $19.0M+7873.9% | $238K-96.6% | $7.0M-90.9% | $76.9M+1372.5% | $5.2M-56.7% | $12.1M+3742.4% | $314K | $0 | N/A | $9.7M+170.2% | $3.6M-30.7% | $5.2M+25.6% | $4.1M |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | $116K | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
BCLI Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity | N/A | N/A | N/A | N/A | -126.4%-36.7pp | -89.7% | N/A | -278.1%-193.8pp | -84.2%-33.9pp | -50.3%+9.8pp | -60.1%+78.4pp | -138.5%+40.3pp | -178.9%-92.7pp | -86.1%+177.2pp | -263.3% |
| Return on Assets | N/A | N/A | -408.6%-121.3pp | -287.3%-203.7pp | -83.5%-21.5pp | -62.1%+293.8pp | -355.9%-231.7pp | -124.2%-80.9pp | -43.4%+2.9pp | -46.3%+3.4pp | -49.7%+43.6pp | -93.3%+10.4pp | -103.7%-36.9pp | -66.8%+76.0pp | -142.8% |
| Current Ratio | 0.030.0x | 0.04-0.2x | 0.24-0.1x | 0.35-3.3x | 3.69-0.2x | 3.85+3.7x | 0.19-1.5x | 1.65-0.1x | 1.74-10.4x | 12.09+6.4x | 5.69+2.6x | 3.08-0.3x | 3.34-0.9x | 4.22+2.2x | 2.03 |
| Debt-to-Equity | N/A | N/A | N/A | N/A | 0.51+0.1x | 0.45 | N/A | 1.24+0.3x | 0.94+0.9x | 0.09-0.1x | 0.21-0.3x | 0.48-0.2x | 0.73+0.4x | 0.29-0.6x | 0.84 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$10.0M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.03), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Where Brainstorm Cell Therapeutics I Ranks
Frequently Asked Questions
What are Brainstorm Cell Therapeutics I's total assets?
Brainstorm Cell Therapeutics I (BCLI) had $1.0M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Brainstorm Cell Therapeutics I spend on research and development?
Brainstorm Cell Therapeutics I (BCLI) invested $4.2M in research and development during fiscal year 2025.
What is Brainstorm Cell Therapeutics I's current ratio?
Brainstorm Cell Therapeutics I (BCLI) had a current ratio of 0.03 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
Why is Brainstorm Cell Therapeutics I's debt-to-equity ratio negative or not reported?
Brainstorm Cell Therapeutics I (BCLI) has negative shareholder equity of -$10.0M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.